Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
To determine the potential for additive or synergistic effects of combination therapy with the selective anti–tumor necrosis factor α agent etanercept and the anti–interleukin‐1 agent anakinra.
Two hundred forty‐four patients in whom rheumatoid arthritis (RA) was active despite methotrexate therapy were treated with subcutaneous etanercept only (25 mg twice weekly), full‐dosage etanercept (25 mg twice weekly) anakinra (100 mg/day), or half‐dosage etanercept (25 mg once weekly) anakinra (100 mg/day) for 6 months in a double‐blind study at 41 centers in the US. Patients had never previously received anticytokine therapy. Patient response was measured with the American College of Rheumatology (ACR) core set criteria, a health‐related quality‐of‐life questionnaire, and the Disease Activity Score. Safety was assessed by the number of adverse events and clinical laboratory values. Plasma concentrations of both agents and antibody formation against both agents were also assessed.
Combination therapy with etanercept anakinra provided no treatment benefit over etanercept alone, regardless of the regimen, but was associated with an increased safety risk. Thirty‐one percent of the patients treated with full‐dosage etanercept anakinra achieved an ACR 50% response, compared with 41% of the patients treated with etanercept only. This result was not statistically significant (P = 0.914). The incidence of serious infections (0% for etanercept alone, 3.7–7.4% for combination therapy), injection‐site reactions, and neutropenia was increased with combination therapy. Combination therapy had no effect on the pharmacokinetics or immunogenicity of either agent.
Combination therapy with etanercept and anakinra provides no added benefit and an increased risk compared with etanercept alone and is not recommended for the treatment of patients with RA.
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by inflammation that often leads to the progressive destruction of articular structures and significant disability. The etiology of RA remains unclear, but it is thought to be mediated in part by antigen‐driven T cells and macrophages that produce interleukin‐1 (IL‐1) and tumor necrosis factor α (TNFα), 2 cytokines involved in the inflammatory cascade (1-3). Specific blockade of these individual cytokines has recently been shown in large, place‐controlled trials to be safe and effective in the treatment of RA (4-9).
Although selective anticytokine therapy has improved patient outcomes, it does not necessarily produce disease remission. Thus, the more aggressive treatment option of combining anticytokine agents has been explored in animal studies. Combination treatment with anakinra, a recombinant IL‐1 receptor antagonist (IL‐1Ra) (Kineret; Amgen, Thousand Oaks, CA), and polyethylene glycol–conjugated soluble TNF receptor type I resulted in synergistic improvement in the symptoms of adjuvant‐induced and collagen‐induced arthritis in rats relative to the improvement observed with either agent alone (10, 11). Additive or synergistic improvement was seen with a variety of dose combinations of each agent, but synergistic improvement was particularly evident when suboptimal doses of each agent were given in combination.
The present study was designed to test the hypothesis that combination therapy with the anti‐TNF agent etanercept, a soluble TNFα receptor (Enbrel; Amgen), and the anti–IL‐1 agent anakinra at their approved dosages would safely provide superior efficacy relative to etanercept alone in patients with RA. Secondarily, the study examined the possibility that anakinra given with etanercept at a dosage of 25 mg once weekly (half the approved weekly dose) would still provide superior efficacy compared with full‐dosage etanercept alone.
PATIENTS AND METHODS
This study enrolled patients who were at least 18 years old and had a >6‐month history of RA, as diagnosed by the American College of Rheumatology (ACR) classification criteria (12). Patients had at least 6 swollen joints and 9 tender/painful joints and at least 2 of the following: morning stiffness lasting at least 45 minutes, a serum C‐reactive protein (CRP) level of at least 1.5 mg/dl, or an erythrocyte sedimentation rate (ESR) of at least 28 mm/hour. Patients had received methotrexate (MTX) for at least 16 weeks, with the dosage stable at 10–25 mg/week for at least 8 weeks. All patients gave informed consent, and the study protocol was approved by the institutional review boards for each study site.
Patients were not eligible to enroll in the study if they had received any disease‐modifying antirheumatic drug other than MTX within the past 4 weeks, had ever been treated with anakinra or any protein‐based TNFα inhibitor (e.g., etanercept, infliximab), had received any intraarticular or systemic corticosteroid injections within the past 4 weeks, or had a recent history of significant infection or other important concurrent illness.
Study design and treatment
Patients were randomly assigned in a 1:1:1 ratio to receive 25 mg of etanercept twice weekly anakinra placebo once daily, 25 mg of etanercept once weekly 100 mg of anakinra daily, or 25 mg of etanercept twice weekly 100 mg of anakinra once daily (hereafter referred to a etanercept only, half‐dosage etanercept anakinra, and full‐dosage etanercept anakinra, respectively). Both etanercept and anakinra were administered subcutaneously for 24 weeks. In order to blind patients to the treatment assignment, additional sham injections of etanercept were administered as necessary, so that all patients received twice weekly injections of etanercept/sham and once daily injections of anakinra or matched placebo. Patients continued to receive stable doses of MTX and other medications (e.g., corticosteroids) throughout the study. After screening, patients were evaluated at baseline (day 1) and at weeks 2, 4, 8, 12, 16, 20, and 24, with followup evaluation 4 weeks after completion or at the time of early discontinuation.
Endogenous human IL‐1Ra was isolated, purified, and produced by recombinant DNA technology using Escherichia coli fermentation. The resulting product, anakinra, is identical to the naturally occurring nonglycosylated form of human IL‐1Ra except for the addition of an N‐terminal methionine residue. Anakinra was provided by Amgen in single‐use vials as a liquid containing 1 ml of 100 mg/ml anakinra. The formulation consisted of sodium citrate, sodium chloride, disodium EDTA, and polysorbate 80. The placebo formulation was the same, but without anakinra. Both solutions were pH 6.5.
Etanercept is a soluble TNF receptor fusion protein produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system. Etanercept was supplied by Amgen in 25‐mg single‐use vials containing etanercept lyophilized powder, mannitol, sucrose, and tromethamine. After reconstitution with bacteriostatic water, the solution had a mean (±SD) pH of 7.4 ± 0.3.
At every study visit, patients were assessed for the components of the ACR core set of disease activity measures (13), the modified Disease Activity Score (DAS) (14), the European League Against Rheumatism (EULAR) response (14), and the duration of morning stiffness. A health‐related quality‐of‐life evaluation with the Short Form 36 (SF‐36) healthy survey (15) was performed at baseline and at weeks 4, 12, and 24 (or at the time of early termination).
The primary end point was the proportion of patients achieving an ACR 50% (ACR50) response (16) at week 24. Secondary efficacy end points included the ACR20 and ACR70 response rates at week 24, the ACR response at week 12, the sustained ACR20 response (response for at least 4 monthly measurements, not necessarily consecutive, with 1 occurring at month 6), a good or moderate EULAR response at week 24, improvement in the ACR core criteria components, duration of morning stiffness, the DAS, and the SF‐36 score.
Patients were considered ACR50 responders if they had at least a 50% reduction in the number of tender and swollen joints and in 3 of the following 5 measures: patient's assessment of disease activity by visual analog scale (VAS), physician's assessment of disease activity by VAS, patient's assessment of pain by VAS, the disability score as measured by the Health Assessment Questionnaire (17), and acute‐phase reactants (CRP or ESR). The joint counts (66 joints evaluated for swelling, and 68 joints evaluated for tenderness/pain) were assessed by the same qualified independent assessors at each study center throughout the study. To preserve blinding of the study, injection sites were covered with clothing during the joint counts to insure that the assessors would not be influenced by injection‐site reactions.
Safety and pharmacokinetic assessment
Safety assessment data that were collected at every study visit were the number of adverse events/infectious events and the clinical laboratory values. An adverse event was defined as follows: “Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment” (18). A serious adverse event was defined as follows: “Any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect” (18).
Blood samples were collected for measurement of plasma anakinra and etanercept concentrations (at baseline and weeks 4, 12, and 24 [or at the time of early termination]) and anti‐anakinra and anti‐etanercept antibodies (at baseline and weeks 12 and 24 [or at the time of early termination]). Plasma anakinra concentrations were assessed by antibody‐capture enzyme‐linked immunoassay (ELISA), and plasma etanercept concentrations were assessed by a solid‐phase sandwich ELISA kit. Antibody samples testing positive in a screening biosensor immunoassay (Biacore, Uppsala, Sweden) were retested for neutralizing antibodies, using a bioassay.
Results were analyzed using a modified intent‐to‐treat method that included all randomized patients who received at least 1 dose each of anakinra/placebo and etanercept/sham. Patients with missing ACR scores at a particular visit were considered nonresponders at that visit.
The primary comparison was the full‐dosage etanercept anakinra group against the etanercept‐only group. The analysis was 1‐tailed for the primary comparison and 2‐tailed for the secondary comparisons. Odds ratios (ORs) and their confidence intervals (CIs) were calculated for comparisons between groups. Binary efficacy end points were analyzed using a logistic regression model. Continuous end points were analyzed over time using a repeated‐measures mixed model.
Adverse events were tabulated for comparison across treatment groups, and summary statistics were calculated for laboratory values.
Characteristics of the study patients.
The baseline demographics and disease characteristics of the patients are shown in Table 1. Most of the patients were women with long‐standing and very active disease. Characteristics were balanced across treatment groups. Completion rates ranged from 78% to 93%, with the highest rate in the etanercept‐only group (Figure 1). Significantly fewer patients in this group withdrew as a result of adverse events compared with the combination‐therapy groups.
|Characteristic||Etanercept only (n = 80)||Half‐dosage etanercept + anakinra (n = 81)||Full‐dosage etanercept + anakinra (n = 81)|
|% white race||86.3||77.8||75.3|
|Age, years||54.4 ± 13.6||53.8 ± 11.8||55.7 ± 13.0|
|% age ≥ 65 years||25.0||18.5||29.6|
|Weight, kg||75 ± 18||82 ± 21||80 ± 23|
|Duration of RA, years||9.7 ± 9.4||9.5 ± 10.3||10.6 ± 9.8|
|% rheumatoid factor positive||65.0||75.3||71.6|
|% receiving corticosteroids||48.8||54.3||44.4|
|NSAID use, %||96.3||95.1||96.3|
|MTX dosage, mg/week||16.1 ± 4.5||16.2 ± 4.2||15.7 ± 5.0|
|No. of tender/painful joints||31.0 ± 14.2||31.0 ± 15.4||35.9 ± 14.9|
|No. of swollen joints||21.4 ± 9.4||19.8 ± 9.6||23.4 ± 12.0|
|HAQ score||1.5 ± 0.6||1.5 ± 0.6||1.6 ± 0.6|
|Serum CRP, mg/dl||2.0 ± 2.2||2.4 ± 3.5||2.0 ± 2.5|
|ESR, mm/hour||44.6 ± 21.51||49.2 ± 22.81||49.9 ± 23.94|
|Duration of morning stiffness, minutes||145.3 ± 102.3||154.4 ± 162.1||159.5 ± 134.0|
|Physical component||28.7 ± 9.7||28.8 ± 7.9||29.1 ± 7.9|
|Mental component||46.9 ± 12.3||47.9 ± 10.9||44.5 ± 11.9|
- * Except where indicated otherwise, values are the mean ± SD. Etanercept only = etanercept 25 mg twice weekly; half‐dosage etanercept + anakinra = etanercept 25 mg once weekly anakinra 100 mg daily; full‐dosage etanercept + anakinra = etanercept 25 mg twice weekly anakinra 100 mg daily; RA = rheumatoid arthritis; NSAID = nonsteroidal antiinflammatory drug; MTX = methotrexate; HAQ = Health Assessment Questionnaire; CRP = C‐reactive protein; ESR = erythrocyte sedimentation rate; SF‐36 = Short Form 36.
Patients in all treatment groups showed improvement from baseline at week 24 (Figure 2). Therapy in the etanercept‐only group resulted in an ACR50 of 41%, compared with 31% in the full‐dosage etanercept anakinra group (P = 0.914, by 1‐tailed t‐test). The OR for achieving an ACR50 response in the full‐dosage etanercept anakinra group relative to that in the etanercept‐only group was 0.64 (90% CI 0.37–1.09). The OR for achieving an ACR50 response in the etanercept‐only group relative to that in the half‐dosage etanercept anakinra group was 1.11 (95% CI 0.59–2.09). For the comparison of patients in the full‐dosage (twice weekly) combination‐therapy group relative to those in the low‐dosage (once weekly) combination therapy group, the OR was 0.71 (95% CI 0.37–1.35).
Because the dropout rate was higher in the groups receiving combination therapy, it was important to determine whether this influenced the efficacy results. Sensitivity analyses, including a completers analysis (all patients who completed the study) and a last observation carried forward analysis, yielded results similar to those observed in the modified intent‐to‐treat analysis (data not shown), indicating that differential dropout rates did not influence the outcome. In addition, results were unaffected when they were adjusted for baseline covariates (data not shown).
Evaluation of the ACR20 and ACR70 response rates confirmed that combination therapy was not superior to etanercept alone. The only comparison yielding a statistically significant difference between treatments indicated that at week 24, the ACR20 response of patients treated with etanercept alone was superior to that of patients treated with etanercept once weekly anakinra (OR 1.98, 95% CI 1.05–3.78; P = 0.037).
Between 43% and 54% of patients in each treatment group achieved a sustained ACR20 response during the study, and most patients achieved a EULAR response at week 24 (79% of patients in etanercept‐only group, 73% of those in the full‐dosage etanercept anakinra group, and 66% of patients in the half‐dosage etanercept anakinra group received a good or moderate rating). At week 24, the mean percent reduction from baseline in the DAS was 39% in the etanercept‐only group, 40% in the half‐dosage etanercept anakinra group, and 41% in the full‐dosage etanercept anakinra group. Radiographs were not obtained in this study.
Plasma concentrations for weeks 4, 12, and 24 indicated that the pharmacokinetic steady state was reached by week 4 for both etanercept and anakinra, and thus the data for all visits were pooled for analysis. The pharmacokinetics of each agent appeared unaffected by the concomitant administration of the other (Figures 3 and 4). Plasma concentrations of anakinra and etanercept were similar to those observed in previous studies of anakinra or etanercept alone (Genovese MC, et al: unpublished observations).
The proportion of patients reporting adverse events was similar for each treatment group (90–95%) (Table 2). However, combination therapy with anakinra and etanercept was associated with a higher overall incidence of serious adverse events, events causing patient withdrawal from study, and injection‐site reactions.
|Event||Etanercept only (n = 80)||Half‐dosage etanercept + anakinra (n = 81)||Full‐dosage etanercept + anakinra (n = 81)|
|Any adverse event||72 (90.0)||77 (95.1)||76 (93.8)|
|Most common adverse events|
|Injection‐site reaction||32 (40.0)||55 (67.9)||57 (70.4)|
|Upper respiratory infection||16 (20.0)||9 (11.1)||11 (13.6)|
|Any adverse event causing withdrawal||0 (0)||7 (8.6)||6 (7.4)|
|Any serious adverse event||2 (2.5)||4 (4.9)||12 (14.8)|
|Any infection||32 (40.0)||30 (37.0)||38 (46.9)|
|Infection resulting in antibiotic administration or hospitalization||0 (0.0)||3 (3.7)||6 (7.4)|
|Infection leading to withdrawal||0 (0.0)||2 (2.5)||2 (2.5)|
|Serious infection||0 (0)||3 (3.7)||6 (7.4)|
|Serious pneumonia||0 (0)||1 (1.2)||2 (2.5)|
|Serious cellulitis||0 (0)||1 (1.2)||2 (2.5)|
- * Values are the number (%) of patients. See Table 1 for definitions.
Serious adverse events were generally individual occurrences, with no single category of event accounting for the increase observed with combination therapy (Table 3). However, infections accounted for serious events in 9 of 16 patients receiving combination therapy. The reported serious infections were as follows: pneumonia and cellulitis (3 patients each), herpes zoster (1 patient), pneumonitis (1 patient), and pyelonephritis (1 patient). One 70‐year‐old patient with pulmonary fibrosis was diagnosed as having pneumonia and died of pulmonary insufficiency. Serious infections occurred an average of 2 months after exposure to combination treatment (range 1 week to 5 months) in patients whose mean age was 60 years (range 42–77 years). No cases of tuberculosis or opportunistic infections were reported.
|Event||Etanercept only (n = 80)||Half‐dosage etanercept + anakinra (n = 81)||Full‐dosage etanercept + anakinra (n = 81)|
|Cellulitis||0 (0)||1 (1.2)||2 (2.5)|
|Pneumonia||0 (0)||1 (1.2)||1 (1.2)|
|Pneumonia and pulmonary fibrosis leading to respiratory insufficiency||0 (0)||0 (0)||1 (1.2)|
|Gastroenteritis||0 (0)||0 (0)||1 (1.2)|
|Herpes zoster||0 (0)||0 (0)||1 (1.2)|
|Lymphoma, malignant||0 (0)||0 (0)||1 (1.2)|
|Neuralgia||0 (0)||0 (0)||1 (1.2)|
|Back pain||0 (0)||0 (0)||1 (1.2)|
|Chest pain, cardiac||0 (0)||0 (0)||1 (1.2)|
|Chest pain, noncardiac||0 (0)||0 (0)||1 (1.2)|
|Pyelonephritis||0 (0)||0 (0)||1 (1.2)|
|Transient ischemic attack||0 (0)||0 (0)||1 (1.2)|
|Arrhythmia, atrial||1 (1.3)||0 (0)||0 (0)|
|Dyspnea||0 (0)||1 (1.2)||0 (0)|
|Gastric ulcer, hemorrhage||0 (0)||1 (1.2)||0 (0)|
|Personality disorder||1 (1.3)||0 (0)||0 (0)|
|Pneumonitis||0 (0)||1 (1.2)||0 (0)|
- * Values are the number (%) of patients. See Table 1 for definitions
The incidence of injection‐site reactions was more than 50% higher with combination therapy than with etanercept alone. These reactions were transient, rarely severe (a combined incidence of 2% in the combination‐therapy groups), and typically involved no clinical sequelae. However, they were the most common cause of adverse event–related withdrawal during the study for patients receiving combination therapy, accounting for 5 of 13 adverse event–related withdrawals. Injection‐site reactions were less likely to occur after the first month of therapy.
The mean neutrophil counts decreased to a similar extent in all 3 groups within the first 2 weeks of initiating treatment but remained stable thereafter. Two patients in the full‐dosage etanercept anakinra group experienced neutropenia (neutrophil count <1.0 × 109/liter) during the study. Both patients completed the study, and no clinical events were associated with the neutropenia. No subjects had changes in the neutrophil count that appeared to be associated with their serious infectious episodes. None of the subjects who experienced serious infectious episodes experienced neutropenia. No other clinically significant trends in the laboratory results were apparent. Three patients receiving anakinra and no patients receiving etanercept had evidence of potentially neutralizing anti‐anakinra and anti‐etanercept antibodies, respectively. The presence of antibodies had no apparent effect on efficacy or safety.
The clinical hypothesis for this study, that combination treatment with selective anticytokine therapies (etanercept and anakinra) would safely provide superior improvement in the signs and symptoms of RA compared with etanercept alone, proved false. Analyses of the primary efficacy end point, the ACR50 response at week 24, showed no significant differences between groups regardless of the combination regimen used (etanercept twice weekly or once weekly). In fact, patients who received etanercept only in this study had the highest ACR responses, similar to those seen in previous studies of etanercept (4, 8), and encountered the fewest safety problems.
Results of preclinical experiments suggested that simultaneous blockade of IL‐1 and TNFα would be more effective than either approach alone in inhibiting progression of RA, with a combination of suboptimal doses of each anticytokine agent providing a synergistic effect. The reasons for the discrepancy between the preclinical and clinical results are unclear, but several theories present themselves. First, there may have been a negative interaction between the compounds. This theory seems unlikely, because the pharmacokinetic results show that plasma concentrations for both agents remained unchanged relative to observations for each agent independently. Also, anakinra is eliminated renally (19-21), while etanercept is eliminated by the Kupffer cells of the liver (Genovese MC, et al: unpublished observations). It is also unlikely that anakinra and etanercept would bind and block the effect of each other.
Second, anti‐anakinra antibodies could be responsible for the lack of benefit of combination therapy. This too is unlikely, because a low percentage of patients had potentially neutralizing anti‐anakinra antibodies, and the antibody results from this study were consistent with the antibody data from other anakinra studies in which efficacy was demonstrated. Third, anti‐TNF therapy could have down‐regulated IL‐1 expression, rendering any impact of anti–IL‐1 therapy negligible. This remains a possibility, although it would not explain the inconsistency between the clinical and preclinical results. Fourth, the degree of overlap and interplay between IL‐1 and TNF may leave little room for improvement beyond the efficacy attainable with an effective TNF inhibitor. This is an intriguing possibility that requires further study.
The safety results for this study showed that combination anticytokine therapy was associated with a higher incidence of serious infections than was observed with the use of etanercept alone. These results are comparable with what was previously reported in a small open‐label study of the combination of etanercept and anakinra (22). Many patients in this study were receiving a combination of 4 potentially immunosuppressive agents, including corticosteroids, MTX, anakinra, and etanercept, all of which could have contributed to this finding. Combination therapy was also more commonly associated with neutropenia, which is probably not surprising because decreases in the neutrophil count have been associated with both etanercept and anakinra (Genovese MC, et al: unpublished observations). It is notable, however, that in this study neutropenia was not associated with the risk of serious infection.
These results suggest that use of combination treatment with anakinra and etanercept is not justified in patients with RA who are naive to biologic therapy. However, the possibility that combination anticytokine treatment could benefit certain patients cannot be excluded based on this relatively small study. The response to combination therapy might be different in patients with partial or inadequate responses to prior anticytokine treatment, for example, although the safety concerns raised by this study would remain. Furthermore, these results do not preclude the possibility of successful combination therapy with future agents selectively blocking other pathways.
Overall, the results from this study provide no evidence of an additional treatment benefit of combination therapy with etanercept anakinra in patients with active RA despite the use of MTX. In fact, the combination posed an increased risk of serious infection and neutropenia. Treatment with etanercept or anakinra alone, or either agent in combination with MTX, has been demonstrated to be effective and safe in previous studies, and the findings from this study do not affect the profiles of the individual compounds. The findings do raise important questions about the role of each of these cytokines in the pathophysiology of RA and other inflammatory diseases. The development of anticytokine therapies has epitomized the translation of research from bench to bedside, and the results of this study highlight the need to translate these results back to the bench to better understand the interrelationship of these cytokines in human disease and to explain the incongruity of the preclinical and clinical findings.
We thank Bing Bing Yang for assistance with the pharmacokinetic analyses, Thomas Liu and Tenshang Joh for assistance with the statistical analysis, and Steve Fletcher for assistance with the manuscript.
MEMBERS OF THE 20000223 STUDY GROUP
Members of the 20000223 Study Group, in addition to the authors of this article, are as follows: S. Block (Bangor, ME), M. Borofsky (West Reading, PA), J. Box (Charlotte, NC), R. Brasington (St. Louis, MO), A. Brodsky (Dallas, TX), K. Bulpitt (Los Angeles, CA), J. Caldwell (Gainesville, FL), R. Coalson (Beavercreek, OH), J. Cush (Dallas, TX), A. Deadhar (Portland, OR), G. Divittorio (Mobile, AL), A. Fishman (Atlanta, GA), M. Greenwald (Rancho Mirage, CA), E. Hurd (Dallas, TX), J. Kay (Burlington, MA), A. Kavanaugh (La Jolla, CA), M. Kohen (South Daytona Beach, FL), S. Maestrello (Richmond, VA), R. Malamet (Hagerstown, MD), D. Mandel (Mayfield Village, OH), R. Martin (Grand Rapids, MI), S. Mathews (South Jacksonville, FL), M. Pearson (Brookfield, WI), J. Poiley (Orlando, FL), T. Romano (Los Angeles, CA), S. Roth (Phoenix, AZ), J. Rutstein (San Antonio, TX), M. Schiff (Denver, CO), M. Schweitz (West Palm Beach, FL), W. Shergy (Huntsville, AL), H. Staley (Indianapolis, IN), G. Sultany (Portland, OR), W. Surbeck (Tulsa, OK), J. Taborn (Kalamazoo, MI), P. Valen (La Crosse, WI), R. Valente (Lincoln, NE), D. Wallace (Los Angeles, CA), C. Weidmann (Van Nuys, CA).
- 1 Utsinger PD, Zvaifler NJ, Ehrlich GE, editors. Rheumatoid arthritis, etiology, diagnosis, and therapy. Philadelphia: Lippincott; 1985.
- 2 Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277–89.
- 3 Arend WP, Dayer J‐M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15.
- 4 Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
- 5 Bresnihan B, Alvaro‐Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist. Arthritis Rheum 1998; 41: 2196–204.
- 6 Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: results of a twenty‐four–week, multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2002; 46: 614–24.
- 7 Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443–50.
- 8 Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9.
- 9 Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, and the Anti‐Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602.
- 10 Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin‐1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 2648–59.
- 11 Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti‐interleukin‐1 and anti‐tumor necrosis factor‐α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci 2000; 57: 1457–70.
- 12 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
- 13 Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729–40.
- 14 Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34–40.
- 15 Ware JE, Kosinski M, Keller S. SF‐36 physical and mental health summary scales: a user's manual. Boston: The Health Assessment Lab, New England Medical Center; 1994.
- 16 Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
- 17 Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
- 18 ICH Guidelines. 21 CFR. Sect. 312.32 (Revised as of April 1, 2003).
- 19 Yang B, Baughman S, Frazier J, Hollifield A, Yates W, Lescale‐Matys L, et al. Pharmacokinetics (PK) of anakinra in subjects with various degrees of renal function. Clin Pharmacol Ther [abstract] 2002; 71: 14.
- 20 Yang B, Baughman S, Sullivan JT. The kidney is the major organ of elimination of Kineret (anakinra). Ann Rheum Dis 2002; 61 Suppl 2: 203.
- 21 Yang B, Baughman, S, Sullivan J. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther 2003; 74: 85–94.
- 22 Schiff MH, Bulpitt K, Weaver AA, Genovese MC, Cohen S, Furst D, et al. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S79.
Number of times cited according to CrossRef: 283
- Tilmann Kallinich and Fabrizio de Benedetti, Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases, Textbook of Autoinflammation, 10.1007/978-3-319-98605-0_41, (751-774), (2019).
- S. Ben‐Horin, B. Ungar, U. Kopylov, A. Lahat, M. Yavzori, E. Fudim, O. Picard, Y. Peled, R. Eliakim, E. Del Tedesco, S. Paul and X. Roblin, Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor, Alimentary Pharmacology & Therapeutics, 47, 8, (1117-1125), (2018).
- Taio Naniwa, Shiho Iwagaitsu and Mikiko Kajiura, Long‐term efficacy and safety of add‐on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors, International Journal of Rheumatic Diseases, 21, 3, (673-687), (2018).
- Philip J. Mease, Mark C. Genovese, Michael E. Weinblatt, Paul M. Peloso, Kun Chen, Ahmed A. Othman, Yihan Li, Heikki T. Mansikka, Amit Khatri, Neil Wishart and John Liu, Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate, Arthritis & Rheumatology, 70, 11, (1778-1789), (2018).
- Ross J. Thibodaux, Mallory W. Triche and Luis R. Espinoza, Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review, Expert Opinion on Biological Therapy, 10.1080/14712598.2018.1492545, 18, 7, (821-827), (2018).
- Robert P. Hirten, Marietta Iacucci, Shailja Shah, Subrata Ghosh and Jean-Frederic Colombel, Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders, Clinical Gastroenterology and Hepatology, 10.1016/j.cgh.2018.02.024, (2018).
- Paul Emery, Janet E. Pope, Klaus Kruger, Ralph Lippe, Ryan DeMasi, Sadiq Lula and Blerina Kola, Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review, Advances in Therapy, 10.1007/s12325-018-0757-2, 35, 10, (1535-1563), (2018).
- E. Michael Lewiecki, New and emerging concepts in the use of denosumab for the treatment of osteoporosis, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X18805759, 10, 11, (209-223), (2018).
- Leonieke J.J. van Mens, Marleen G.H. van de Sande and Dominique L.P. Baeten, New treatment paradigms in spondyloarthritis, Current Opinion in Rheumatology, 10.1097/BOR.0000000000000457, 30, 1, (79-86), (2018).
- Arthur N. Lau, Matthew Wong-Pack, Rod Rodjanapiches, George Ioannidis, Sally Wade, Leslie Spangler, Akhila Balasubramanian, Nicola Pannacciulli, Celia J.F. Lin, Patrick Roy-Gayos, William G. Bensen, Robert Bensen and Jonathan D. Adachi, Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting, The Journal of Rheumatology, 10.3899/jrheum.161270, 45, 2, (170-176), (2017).
- Mark C. Genovese, Michael E. Weinblatt, Jacob A. Aelion, Heikki T. Mansikka, Paul M. Peloso, Kun Chen, Yihan Li, Ahmed A. Othman, Amit Khatri, Nasser S. Khan and Robert J. Padley, ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate, Arthritis & Rheumatology, 70, 11, (1710-1720), (2018).
- Shekoufeh Nikfar, Parisa Saiyarsarai, Bereket Molla Tigabu and Mohammad Abdollahi, Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis, Rheumatology International, 10.1007/s00296-018-4041-1, 38, 8, (1363-1383), (2018).
- Gonçalo Boleto, Lukshe Kanagaratnam, Moustapha Dramé and Jean-Hugues Salmon, Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis, Seminars in Arthritis and Rheumatism, 10.1016/j.semarthrit.2018.12.003, (2018).
- Laurent Peyrin-Biroulet, Stephen Demarest and Ajay Nirula, Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies, Autoimmunity Reviews, 10.1016/j.autrev.2018.07.014, (2018).
- Kate Senger, Victoria C. Pham, Eugene Varfolomeev, Jason A. Hackney, Cesar A. Corzo, Jenna Collier, Vivian W. C. Lau, Zhiyu Huang, Kajal Hamidzhadeh, Patrick Caplazi, Ivan Peng, A. Francesca Setiadi, Ross Francis, Andres Paler-Martinez, Youngsu C. Kwon, Vladimir Ramirez-Carrozzi, Yonglian Sun, Patricia W. Grigg, Merone Roose-Girma, Surinder Jeet, Kai H. Barck, Anna Pham, Naruhisa Ota, Connie Ha, Jeremy Stinson, Joseph Guillory, Lucinda Tam, Zora Modrusan, Claire Emson, Brent S. McKenzie, Michael J. Townsend, Richard A. D. Carano, Søren Warming, Domagoj Vucic, Jason DeVoss, Wyne P. Lee, Jennie R. Lill and Ali A. Zarrin, The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation, Science Signaling, 10.1126/scisignal.aah4273, 10, 475, (eaah4273), (2017).
- Balaji Banoth and Fayyaz S. Sutterwala, Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes, Journal of Clinical Investigation, 10.1172/JCI98322, (2017)., (2017).
- Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, Roberto Perez-Alvarez, Pilar Brito-Zerón and Manuel Ramos-Casals, Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry), Expert Opinion on Drug Safety, 10.1080/14740338.2017.1372421, 16, 11, (1255-1271), (2017).
- L. Xing and J. Mathias, Medicinal Chemistry Case History: Structure-Based Drug Design of Oral and Inhaled p38 MAP Kinase Inhibitors as Clinical Candidates, Comprehensive Medicinal Chemistry III, 10.1016/B978-0-12-409547-2.12458-8, (408-430), (2017).
- Zuhre Tutuncu and Arthur Kavanaugh, Anti-cytokine Therapies, Kelley and Firestein's Textbook of Rheumatology, 10.1016/B978-0-323-31696-5.00063-2, (999-1019), (2017).
- Gonçalo Boleto, Moustapha Dramé, Isabelle Lambrecht, Jean-Paul Eschard and Jean-Hugues Salmon, Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature, Clinical Rheumatology, 10.1007/s10067-017-3722-6, 36, 8, (1699-1706), (2017).
- Gary S. Firestein, Etiology and Pathogenesis of Rheumatoid Arthritis, Kelley and Firestein's Textbook of Rheumatology, 10.1016/B978-0-323-31696-5.00069-3, (1115-1166.e7), (2017).
- Matthew D. McGeough, Alexander Wree, Maria E. Inzaugarat, Ariela Haimovich, Casey D. Johnson, Carla A. Peña, Raphaela Goldbach-Mansky, Lori Broderick, Ariel E. Feldstein and Hal M. Hoffman, TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies, Journal of Clinical Investigation, 10.1172/JCI90699, (2017)., (2017).
- Alain C. Tissot and Ulrich Brinkmann, Bispecific Antibodies, Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases, 10.1007/978-3-319-42252-7_5, (75-97), (2017).
- James R. O'Dell, Treatment of Rheumatoid Arthritis, Kelley and Firestein's Textbook of Rheumatology, 10.1016/B978-0-323-31696-5.00071-1, (1187-1212.e5), (2017).
- Mélissa Noack and Pierre Miossec, Selected cytokine pathways in rheumatoid arthritis, Seminars in Immunopathology, 10.1007/s00281-017-0619-z, 39, 4, (365-383), (2017).
- Cong-Qiu Chu, Therapeutic Applications: Strategies and Molecules Targeting the IL-17/Th17 Pathway, Targeting the IL-17 Pathway in Inflammatory Disorders, 10.1007/978-3-319-28040-0_5, (55-99), (2016).
- Yoshifumi Itoh, Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies, Matrix Metalloproteinases and Tissue Remodeling in Health and Disease: Target Tissues and Therapy, 10.1016/bs.pmbts.2017.03.002, (327-338), (2017).
- Roy M. Fleischmann, Frank Wagner, Alan J. Kivitz, Heikki T. Mansikka, Nasser Khan, Ahmed A. Othman, Amit Khatri, Feng Hong, Ping Jiang, Melanie Ruzek and Robert J. Padley, Safety, Tolerability, and Pharmacodynamics of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17–Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis, Arthritis & Rheumatology, 69, 12, (2283-2291), (2017).
- R. Gniadecki, B. Bang and C. Sand, Combination of antitumour necrosis factor‐α and anti‐interleukin‐12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long‐term case‐series observational study, British Journal of Dermatology, 174, 5, (1145-1146), (2016).
- Michela Silacci, Wibke Lembke, Richard Woods, Isabella Attinger-Toller, Nadja Baenziger-Tobler, Sarah Batey, Roger Santimaria, Ulrike von der Bey, Susann Koenig-Friedrich, Wenjuan Zha, Bernd Schlereth, Mathias Locher, Julian Bertschinger and Dragan Grabulovski, Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases, mAbs, 10.1080/19420862.2015.1093266, 8, 1, (141-149), (2015).
- T. Torres, M. Romanelli and A. Chiricozzi, A revolutionary therapeutic approach for psoriasis: bispecific biological agents, Expert Opinion on Investigational Drugs, 10.1080/13543784.2016.1187130, 25, 7, (751-754), (2016).
- Marina S. Drutskaya, Grigory A. Efimov, Irina V. Astrakhantseva, Andrei A. Kruglov and Sergei A. Nedospasov, Making anti-cytokine therapy more selective: Studies in mice, Cytokine, 10.1016/j.cyto.2016.08.022, (2016).
- Shivani P. Reddy, Vidhi V. Shah, Elaine J. Lin and Jashin J. Wu, Etanercept, Therapy for Severe Psoriasis, 10.1016/B978-0-323-44797-3.00008-6, (83-96), (2016).
- A. Santimov and A.A. Grom, Other Biological Therapies for Pediatric Rheumatic Diseases, Pediatrics in Systemic Autoimmune Diseases, 10.1016/B978-0-444-63596-9.00024-4, (503-525), (2016).
- Peter P. Sordillo, Laura A. Sordillo and Lawrence Helson, Bifunctional role of pro-inflammatory cytokines after traumatic brain injury, Brain Injury, 10.3109/02699052.2016.1163618, 30, 9, (1043-1053), (2016).
- Tadashi Hosoya, Hideyuki Iwai, Yu Yamaguchi, Kimito Kawahata, Nobuyuki Miyasaka and Hitoshi Kohsaka, Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression, Annals of the Rheumatic Diseases, 10.1136/annrheumdis-2014-205566, 75, 1, (253-259), (2014).
- Kazuyo Kaneko, Richard O. Williams, Daniel T. Dransfield, Andrew E. Nixon, Ann Sandison and Yoshifumi Itoh, Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade, Arthritis & Rheumatology, 68, 2, (521-531), (2016).
- Minyoung Her and Arthur Kavanaugh, Alterations in immune function with biologic therapies for autoimmune disease, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2015.10.023, 137, 1, (19-27), (2016).
- Jasvinder A. Singh, Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies, Current Rheumatology Reports, 10.1007/s11926-016-0609-5, 18, 10, (2016).
- Franziska Bootz and Dario Neri, Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions, Drug Discovery Today, 10.1016/j.drudis.2015.10.012, 21, 1, (180-189), (2016).
- Ryota Sakai, Tsuneo Kondo, Jun Kikuchi, Akiko Shibata, Kentaro Chino, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial, Modern Rheumatology, 10.3109/14397595.2016.1160968, 26, 6, (900-907), (2016).
- Kentaro Inui and Tatsuya Koike, Combination therapy with biologic agents in rheumatic diseases: current and future prospects, Therapeutic Advances in Musculoskeletal Disease, 10.1177/1759720X16665330, 8, 5, (192-202), (2016).
- Norman T. Ilowite and Ronald M. Laxer, Pharmacology, Textbook of Pediatric Rheumatology, 10.1016/B978-0-323-24145-8.00013-2, (161-175.e6), (2016).
- Shivani P. Reddy, Elaine J. Lin, Vidhi V. Shah and Jashin J. Wu, Adalimumab, Therapy for Severe Psoriasis, 10.1016/B978-0-323-44797-3.00010-4, (111-126), (2016).
- Marc Feldmann and Ravinder N. Maini, Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis?, Arthritis & Rheumatology, 67, 9, (2283-2291), (2015).
- Isidoro González-Álvaro, Carmen Martínez-Fernández, Benito Dorantes-Calderón, Rosario García-Vicuña, Blanca Hernández-Cruz, Alicia Herrero-Ambrosio, Olatz Ibarra-Barrueta, Emilio Martín-Mola, Emilio Monte-Boquet, Alberto Morell-Baladrón, Raimon Sanmartí, Jesús Sanz-Sanz, Francisco Javier de Toro-Santos, Paloma Vela, José Andrés Román Ivorra, José Luis Poveda-Andrés and Santiago Muñoz-Fernández, Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, Rheumatology, 10.1093/rheumatology/keu461, 54, 7, (1200-1209), (2014).
- Jeffrey R. Curtis, Fenglong Xie, Huifeng Yun, Kenneth G. Saag, Lang Chen and Elizabeth Delzell, Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab, Arthritis & Rheumatology, 67, 6, (1456-1464), (2015).
- Fang Wang, Jiyun Yu, Yu Wang, Yunbo Jiang, Ning Guo and Wei Zhang, Combination therapy with TNFR-Fc and CTLA4-FasL using the recombinant adeno-associated virus potently suppresses adjuvant-induced arthritis in rats, Applied Microbiology and Biotechnology, 10.1007/s00253-015-6459-7, 99, 15, (6327-6337), (2015).
- Carl Orr and Douglas James Veale, Therapeutic targets in psoriatic arthritis, International Journal of Clinical Rheumatology, 10.2217/ijr.15.52, 10, 6, (489-499), (2015).
- Tyler K. Ulland, Polly J. Ferguson and Fayyaz S. Sutterwala, Evasion of inflammasome activation by microbial pathogens, Journal of Clinical Investigation, 10.1172/JCI75254, 125, 2, (469-477), (2015).
- Marije I. Koenders and Wim B. van den Berg, Novel therapeutic targets in rheumatoid arthritis, Trends in Pharmacological Sciences, 10.1016/j.tips.2015.02.001, 36, 4, (189-195), (2015).
- Yasser El Miedany, Co-morbidity index in rheumatoid arthritis: time to think, Clinical Rheumatology, 10.1007/s10067-015-3101-0, 34, 12, (1995-2000), (2015).
- Khaled J. Saleh, Alexander J. Kurdi, Mouhanad M. El-Othmani, Benjamin A. Voss, Tony H. Tzeng, Jasmine Saleh, Joseph M. Lane and William M. Mihalko, Perioperative Treatment of Patients with Rheumatoid Arthritis, Journal of the American Academy of Orthopaedic Surgeons, 10.5435/JAAOS-D-15-00014, 23, 9, (e38-e48), (2015).
- C. Monaco, J. Nanchahal, P. Taylor and M. Feldmann, Anti-TNF therapy: past, present and future, International Immunology, 10.1093/intimm/dxu102, 27, 1, (55-62), (2014).
- Luca Cantarini, Giuseppe Lopalco, Francesco Caso, Luisa Costa, Florenzo Iannone, Giovanni Lapadula, Maria Grazia Anelli, Rossella Franceschini, Cristina Menicacci, Mauro Galeazzi, Carlo Selmi and Donato Rigante, Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease, Autoimmunity Reviews, 10.1016/j.autrev.2014.08.008, 14, 1, (1-9), (2015).
- Manjari Lahiri and William G. Dixon, Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2015.05.009, 29, 2, (290-305), (2015).
- Jens A. A. Fischer, Axel J. Hueber, Stacy Wilson, Margarete Galm, Wolfgang Baum, Christopher Kitson, Johannes Auer, Stefan H. Lorenz, Jörg Moelleken, Martin Bader, Alain C. Tissot, Seng‐Lai Tan, Stefan Seeber and Georg Schett, Combined Inhibition of Tumor Necrosis Factor α and Interleukin‐17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody, Arthritis & Rheumatology, 67, 1, (51-62), (2014).
- Frank R. Brennan, Annick Cauvin, Jay Tibbitts and Alison Wolfreys, Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases, Drug Development Research, 75, 3, (115-161), (2014).
- Alberto Migliore, Eleonora Ballanti, Bruno Laganà, Luis Severino Martin and Bruno Frediani, Biologic agents for rheumatoid arthritis: Can we hypothesize new strategies of treatment?, Medical Hypotheses, 10.1016/j.mehy.2013.08.028, 82, 1, (117-121), (2014).
- Steven M. Opal, Dual Inhibition of Interleukin-1β and Interleukin-18: A New Treatment Option for Sepsis?, American Journal of Respiratory and Critical Care Medicine, 10.1164/rccm.201312-2292ED, 189, 3, (242-244), (2014).
- Elizabeth A. Kessler and Mara L. Becker, Therapeutic advancements in juvenile idiopathic arthritis, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2014.03.005, 28, 2, (293-313), (2014).
- Maya Debbaneh and John Koo, Adalimumab, Moderate to Severe Psoriasis, Fourth Edition, 10.1201/b16633-13, (199-216), (2014).
- Dinny Wallis, Infection risk and biologics, Current Opinion in Rheumatology, 10.1097/BOR.0000000000000072, 26, 4, (404-409), (2014).
- Gary Reynolds, Faye AH Cooles, John D Isaacs and Catharien MU Hilkens, Emerging immunotherapies for rheumatoid arthritis, Human Vaccines & Immunotherapeutics, 10.4161/hv.27910, 10, 4, (822-837), (2014).
- Hideki Kitaura, Keisuke Kimura, Masahiko Ishida, Haruki Sugisawa, Haruka Kohara, Masako Yoshimatsu and Teruko Takano-Yamamoto, Effect of Cytokines on Osteoclast Formation and Bone Resorption during Mechanical Force Loading of the Periodontal Membrane, The Scientific World Journal, 10.1155/2014/617032, 2014, (1-7), (2014).
- Tzeyu L. Michaud, Young Hee Rho, Tatyana Shamliyan, Karen M. Kuntz and Hyon K. Choi, The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials, The American Journal of Medicine, 10.1016/j.amjmed.2014.06.012, 127, 12, (1208-1232), (2014).
- Robert Eisenberg, Immune Compromise Associated with Biologics, Stiehm's Immune Deficiencies, 10.1016/B978-0-12-405546-9.00049-2, (889-906), (2014).
- Cecilia Beatrice Chighizola, Ennio Giulio Favalli and Pier Luigi Meroni, Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases, Clinical Reviews in Allergy & Immunology, 10.1007/s12016-013-8359-x, 47, 1, (6-16), (2013).
- Teresa Hemmerle, Silvana Zgraggen, Mattia Matasci, Cornelia Halin, Michael Detmar and Dario Neri, Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation, Journal of Dermatological Science, 10.1016/j.jdermsci.2014.07.012, 76, 2, (96-103), (2014).
- Mark C. Genovese, Maria Greenwald, Chul‐Soo Cho, Alberto Berman, Ling Jin, Gregory S. Cameron, Olivier Benichou, Li Xie, Daniel Braun, Pierre‐Yves Berclaz and Subhashis Banerjee, A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors, Arthritis & Rheumatology, 66, 7, (1693-1704), (2014).
- Fabia Doll, Kathrin Schwager, Teresa Hemmerle and Dario Neri, Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse, Arthritis Research & Therapy, 10.1186/ar4319, 15, 5, (R138), (2013).
- F. Speth, N. Wellinghausen and J.-P. Haas, Medikamentöse Prophylaxe während intensivierter Immunsuppression bei Kindern und JugendlichenMedicinal prophylaxis during intensified immunosuppression in children and adolescents, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1203-0, 72, 9, (896-909), (2013).
- P. Härle, Kombination von BiologikaCombination of biologics, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1141-x, 72, 9, (878-884), (2013).
- F. Speth, N. Wellinghausen and J.-P. Haas, Vorsorgeuntersuchungen während intensivierter Immunsuppression bei Kindern und JugendlichenScreening investigations during intensified immunosuppression in children and adolescents, Zeitschrift für Rheumatologie, 10.1007/s00393-013-1200-3, 72, 8, (814-821), (2013).
- Bo Xie, Shan Liu, Shuyin Wu, Alan Chang, Weiyuan Jin, Zhixiang Guo, Shuaidong Ye and Mizhou Hui, A Novel Bifunctional Protein TNFR2-Fc-IL-1ra (TFI): Expression, Purification and its Neutralization Activity of Inflammatory Factors, Molecular Biotechnology, 10.1007/s12033-012-9550-7, 54, 2, (141-147), (2012).
- Bernard Combe and Ronald van Vollenhoven, Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples, Annals of the Rheumatic Diseases, 10.1136/annrheumdis-2013-203261, 72, 9, (1433-1435), (2013).
- Nayrton Flávio Moura Rocha, Emiliano Ricardo Vasconcelos Rios, Alyne Mara Rodrigues Carvalho, Leonardo Vasconcelos Freire, Marília Leite Dias, Marta Maria de França Fonteles and Francisca Cléa Florenço de Sousa, Synergistic effect of the l-tryptophan and kynurenic acid with dipyrone or paracetamol in mice, Chemico-Biological Interactions, 10.1016/j.cbi.2013.07.005, 205, 2, (148-156), (2013).
- Zuhre Tutuncu and Arthur Kavanaugh, Anticytokine Therapies, Kelley's Textbook of Rheumatology, 10.1016/B978-1-4377-1738-9.00063-3, (957-977.e4), (2013).
- James R. O'Dell, Treatment of Rheumatoid Arthritis, Kelley's Textbook of Rheumatology, 10.1016/B978-1-4377-1738-9.00071-2, (1137-1160.e4), (2013).
- Lukas Bossaller and Achim Rothe, Monoclonal antibody treatments for rheumatoid arthritis, Expert Opinion on Biological Therapy, 10.1517/14712598.2013.811230, 13, 9, (1257-1272), (2013).
- Licia Maria Henrique da Mota, Bóris Afonso Cruz, Claiton Viegas Brenol, Ivânio Alves Pereira, Lucila Stange Rezende-Fronza, Manoel Barros Bertolo, Max Vitor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada-Junior, Rina Dalva Neubarth Giorgio, Rodrigo Aires Corrêa Lima, Wanderley Marques Bernardo and Geraldo da Rocha Castelar Pinheiro, Guidelines for the drug treatment of rheumatoid arthritis, Revista Brasileira de Reumatologia (English Edition), 10.1016/S2255-5021(13)70020-8, 53, 2, (158-183), (2013).
- Licia Maria Henrique da Mota, Bóris Afonso Cruz, Claiton Viegas Brenol, Ivânio Alves Pereira, Lucila Stange Rezende-Fronza, Manoel Barros Bertolo, Max Vitor Carioca Freitas, Nilzio Antônio da Silva, Paulo Louzada-Junior, Rina Dalva Neubarth Giorgio, Rodrigo Aires Corrêa Lima, Wanderley Marques Bernardo and Geraldo da Rocha Castelar Pinheiro, Diretrizes para o tratamento da artrite reumatoide, Revista Brasileira de Reumatologia, 10.1590/S0482-50042013000200004, 53, 2, (158-183), (2013).
- Wei Zhang, Fang Wang, Jinqi Yan, Xiaojun Zhang, Yu Wang, Yunbo Jiang, Lin Wang, Yuanji Xu and Jiyun Yu, Design, expression and characterization of a novel coexpression system of two antiarthritic molecules, Applied Microbiology and Biotechnology, 10.1007/s00253-013-4787-z, 97, 14, (6301-6314), (2013).
- Marc Cohen, Mohammed A Omair and Edward C Keystone, Monoclonal antibodies in rheumatoid arthritis, International Journal of Clinical Rheumatology, 10.2217/ijr.13.52, 8, 5, (541-556), (2013).
- Gary S. Firestein, Etiology and Pathogenesis of Rheumatoid Arthritis, Kelley's Textbook of Rheumatology, 10.1016/B978-1-4377-1738-9.00069-4, (1059-1108.e5), (2013).
- William F.C. Rigby, Philip J. Mease, Ewa Olech, Mark Ashby and Swati Tole, Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study, The Journal of Rheumatology, 10.3899/jrheum.120924, 40, 5, (599-604), (2013).
- Michael E. Weinblatt, Larry W. Moreland, Rene Westhovens, Roger B. Cohen, Sheila M. Kelly, Nader Khan, Ramesh Pappu, Ingrid Delaet, Allison Luo, Sheila Gujrathi and Marc C. Hochberg, Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program, The Journal of Rheumatology, 10.3899/jrheum.120906, 40, 6, (787-797), (2013).
- M. McCall, R. Pawlick, T. Kin and A. M. J. Shapiro, Anakinra Potentiates the Protective Effects of Etanercept in Transplantation of Marginal Mass Human Islets in Immunodeficient Mice, American Journal of Transplantation, 12, 2, (322-329), (2011).
- Prakash Manikwar, Paul Kiptoo, Ahmed H. Badawi, Barlas Büyüktimkin and Teruna J. Siahaan, Antigen‐specific blocking of CD4‐Specific immunological synapse formation using BPI and current therapies for autoimmune diseases, Medicinal Research Reviews, 32, 4, (727-764), (2011).
- Morihito Takita, Shinichi Matsumoto, Masayuki Shimoda, Daisuke Chujo, Takeshi Itoh, Jeffrey A. SoRelle, Kerri Purcell, Nicholas Onaca, Bashoo Naziruddin and Marlon F. Levy, Safety and tolerability of the T‐cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation, Clinical Transplantation, 26, 5, (E471-E484), (2012).
- Jean-Marie Berthelot, Efficacy of low-dose etanercept (25mg/week): How much do we know?, Joint Bone Spine, 10.1016/j.jbspin.2012.02.008, 79, 4, (335-337), (2012).
- Palanisamy Kanakaraj, Bridget A. Puffer, Xiao-Tao Yao, Spandana Kankanala, Ernest Boyd, Rutul R. Shah, Geping Wang, Dimki Patel, Rajesh Krishnamurthy, Shashi Kaithamana, Rodger G. Smith, David W. LaFleur, Carlos F. Barbas III, David M. Hilbert, Peter A. Kiener and Viktor V. Roschke, Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis, mAbs, 10.4161/mabs.21227, 4, 5, (600-613), (2014).
- M. Gaubitz, Biologika 2012Biologicals 2012, Der Orthopäde, 10.1007/s00132-012-1931-x, 41, 7, (526-532), (2012).
- R. Cascão, B. Vidal, H. Raquel, A. Neves-Costa, N. Figueiredo, V. Gupta, J.E. Fonseca and L.F. Moita, Effective treatment of rat adjuvant-induced arthritis by celastrol, Autoimmunity Reviews, 10.1016/j.autrev.2012.02.022, 11, 12, (856-862), (2012).
- Yasushi Matsuyama, Hitoaki Okazaki, Motoaki Hoshino, Sachiko Onishi, Yasuyuki Kamata, Katsuya Nagatani, Takao Nagashima, Masahiro Iwamoto, Taku Yoshio, Hiromi Ohto-Ozaki, Hiroyuki Tamemoto, Mayumi Komine, Hitoshi Sekiya, Shin-ichi Tominaga and Seiji Minota, Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response, Rheumatology International, 10.1007/s00296-011-1854-6, 32, 5, (1397-1401), (2011).
- Todd A Kerensky, Alice B Gottlieb, Shimrat Yaniv and Shiu-chung Au, Etanercept: efficacy and safety for approved indications, Expert Opinion on Drug Safety, 10.1517/14740338.2012.633509, 11, 1, (121-139), (2011).
- RAQUEL CUCHACOVICH, IGNACIO GARCIA-VALLADARES and LUIS R. ESPINOZA, Combination Biologic Treatment of Refractory Psoriasis and Psoriatic Arthritis, The Journal of Rheumatology, 10.3899/jrheum.110295, 39, 1, (187.2-193), (2012).
- Emma L Williams, Christopher J Edwards, Cyrus Cooper and Richard OC Oreffo, Impact of inflammation on the osteoarthritic niche: implications for regenerative medicine, Regenerative Medicine, 10.2217/rme.12.34, 7, 4, (551-570), (2012).
- Kevin L. Winthrop, Infections and Biologic Therapy in Rheumatoid Arthritis, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2012.08.019, 38, 4, (727-745), (2012).
- Anshuman P. Malaviya and Andrew J. K. Östör, Rheumatoid arthritis and the era of biologic therapy, Inflammopharmacology, 10.1007/s10787-012-0123-y, 20, 2, (59-69), (2012).
- Ananya Mitra, Debasis Bagchi, Siba Raychaudhuri and Smriti Raychaudhuri, Biologics, Chronic Inflammation, 10.1201/b12696-30, (369-390), (2012).
- Rachel Byng-Maddick and Michael Ehrenstein, Infections in biological agents used in rheumatic disease, British Journal of Hospital Medicine, 73, 9, (517), (2012).
- Norman T. Ilowite and Ronald M. Laxer, PHARMACOLOGY AND DRUG THERAPY, Textbook of Pediatric Rheumatology, 10.1016/B978-1-4160-6581-4.10006-8, (71-126), (2011).
- Lee J. Quinton and Joseph P. Mizgerd, NF-κB and STAT3 signaling hubs for lung innate immunity, Cell and Tissue Research, 10.1007/s00441-010-1044-y, 343, 1, (153-165), (2010).
- Kevin L. Winthrop, Infections and biologic therapy in rheumatoid arthritis, Rheumatology, 10.1016/B978-0-323-06551-1.00064-6, (605-610.e2), (2011).
- Jon T. Giles and Joan M. Bathon, Management of rheumatoid arthritis, Rheumatology, 10.1016/B978-0-323-06551-1.00094-4, (955-963.e2), (2011).
- Gerd Horneff, Treatment options with biologics for juvenile idiopathic arthritis, International Journal of Clinical Rheumatology, 10.2217/ijr.11.26, 6, 3, (305-323), (2011).
- Sandhya Girish, Steven W Martin, Mark C Peterson, Lei K. Zhang, Hong Zhao, Joseph Balthasar, Raymond Evers, Honghui Zhou, Min Zhu, Lewis Klunk, Chao Han, Eva Gil Berglund, Shiew-Mei Huang and Amita Joshi, AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development, The AAPS Journal, 10.1208/s12248-011-9285-6, 13, 3, (405-416), (2011).
- John J. Cush and Arthur Kavanaugh, Tumor necrosis factor blocking therapies, Rheumatology, 10.1016/B978-0-323-06551-1.00061-0, (577-596.e3), (2011).
- Jun Bao, Tao Yue, Wei Liu, Qing Zhang, Ling Zhou, Hu-Ji Xu and Sheng-Ming Dai, Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis, Clinical Rheumatology, 10.1007/s10067-010-1654-5, 30, 5, (697-701), (2011).
- Cem Gabay, Cytokine neutralizers, Rheumatology, 10.1016/B978-0-323-06551-1.00060-9, (571-576.e2), (2011).
- Luke L Gompels, Nasser M Malik, Leigh Madden, Pei Jin, Marc Feldmann, H Michael Shepard and Ewa M Paleolog, Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade, Arthritis Research & Therapy, 10.1186/ar3480, 13, 5, (R161), (2011).
- Smriti Raychaudhuri, Biologics, Arthritis, 10.1201/b10852-15, (147-163), (2011).
- Li-Chung Hsu, Thomas Enzler, Jun Seita, Anjuli M Timmer, Chih-Yuan Lee, Ting-Yu Lai, Guann-Yi Yu, Liang-Chuan Lai, Vladislav Temkin, Ursula Sinzig, Thiha Aung, Victor Nizet, Irving L Weissman and Michael Karin, IL-1β-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKKβ, Nature Immunology, 10.1038/ni.1976, 12, 2, (144-150), (2010).
- Josef S. Smolen, Maarten Boers, Eric C. Abadie, Ferdinand C. Breedveld, Paul Emery, Thomas Bardin, Niti Goel, Dominique J. Ethgen, Bernard P. Avouac, Willard H. Dere, Patrick Durez, Marco Matucci-Cerinic, Bruno Flamion, Andrea Laslop, Frits J. Lekkerkerker, Pierre Miossec, Bruce H. Mitlak, Sif Ormarsdóttir, Laurence Paolozzi, Ravi Rao, Susan Reiter, Yannis Tsouderos and Jean-Yves Reginster, Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA, Current Medical Research and Opinion, 10.1185/03007995.2010.542135, 27, 2, (315-325), (2010).
- JCF van Luijn, M Danz, JWJ Bijlsma, FWJ Gribnau and HGM Leufkens, Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept, Scandinavian Journal of Rheumatology, 10.3109/03009742.2010.509102, 40, 3, (183-191), (2010).
- Anita Gupta, Elizabeth Hewitt and Charlie Oshinsky, Biomarkers and immunomodulation as a treatment option for chronic pain conditions, Pain Management, 10.2217/pmt.10.3, 1, 1, (81-86), (2011).
- Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, Jacques Blacher, Yoram Bouhnik, Pascal Claudepierre, Arnaud Constantin, Bruno Fautrel, Philippe Gaudin, Vincent Goëb, Laure Gossec, Philippe Goupille, Séverine Guillaume-Czitrom, Eric Hachulla, Isabelle Huet, Denis Jullien, Odile Launay, Marc Lemann, Jean-Francis Maillefert, Jean-Pierre Marolleau, Valérie Martinez, Charles Masson, Jacques Morel, Luc Mouthon, Stanislas Pol, Xavier Puéchal, Pascal Richette, Alain Saraux, Thierry Schaeverbeke, Martin Soubrier, Anne Sudre, Tu-Anh Tran, Manuelle Viguier, Olivier Vittecoq, Daniel Wendling, Xavier Mariette and Jean Sibilia, TNF alpha antagonist therapy and safety monitoring, Joint Bone Spine, 10.1016/S1297-319X(11)70001-X, 78, (15-185), (2011).
- Timothy Beukelman, Nivedita M. Patkar, Kenneth G. Saag, Sue Tolleson‐Rinehart, Randy Q. Cron, Esi Morgan DeWitt, Norman T. Ilowite, Yukiko Kimura, Ronald M. Laxer, Daniel J. Lovell, Alberto Martini, C. Egla Rabinovich and Nicolino Ruperto, 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care & Research, 63, 4, (465-482), (2011).
- Erica D. Dommasch, Katrina Abuabara, Daniel B. Shin, Josephine Nguyen, Andrea B. Troxel and Joel M. Gelfand, The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials, Journal of the American Academy of Dermatology, 10.1016/j.jaad.2010.09.734, 64, 6, (1035-1050), (2011).
- Gary Peltz, Immunomodulation in perioperative medicine, Pain Management, 10.2217/pmt.11.5, 1, 2, (103-106), (2011).
- Arthur F. Kavanaugh, Lloyd F. Mayer, John J. Cush and Stephen B. Hanauer, Shared Experiences and Best Practices in the Management of Rheumatoid Arthritis and Crohn's Disease, The American Journal of Medicine, 10.1016/j.amjmed.2011.01.001, 124, 4, (e1-e18), (2011).
- Jamie Campbell, David Lowe and Matthew A Sleeman, Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis, British Journal of Pharmacology, 162, 7, (1470-1484), (2011).
- JESSICA L. RECORD, TIMOTHY BEUKELMAN and RANDY Q. CRON, Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series: Table 1., The Journal of Rheumatology, 10.3899/jrheum.100726, 38, 1, (180-181), (2011).
- Maria W. Greenwald, William J. Shergy, Jeffrey L. Kaine, Marianne T. Sweetser, Kye Gilder and Matthew D. Linnik, Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial, Arthritis & Rheumatism, 63, 3, (622-632), (2011).
- Jan Bondeson, Arjen B. Blom, Shane Wainwright, Clare Hughes, Bruce Caterson and Wim B. van den Berg, The role of synovial macrophages and macrophage‐produced mediators in driving inflammatory and destructive responses in osteoarthritis, Arthritis & Rheumatism, 62, 3, (647-657), (2010).
- Sougata Karmakar, Jonathan Kay and Ellen M. Gravallese, Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2010.03.003, 36, 2, (385-404), (2010).
- Ioannis Mitroulis, Panagiotis Skendros and Konstantinos Ritis, Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome, European Journal of Internal Medicine, 10.1016/j.ejim.2010.03.005, 21, 3, (157-163), (2010).
- Cem Gabay, Céline Lamacchia and Gaby Palmer, IL-1 pathways in inflammation and human diseases, Nature Reviews Rheumatology, 10.1038/nrrheum.2010.4, 6, 4, (232-241), (2010).
- Jinhyun Kim and Yeong-Wook Song, Medical treatment of rheumatoid arthritis (II): current biologic agents and newly developing drugs, Journal of the Korean Medical Association, 10.5124/jkma.2010.53.10.880, 53, 10, (880), (2010).
- Soo-In Choi and Ernest Brahn, Rheumatoid arthritis therapy: Advances from bench to bedside, Autoimmunity, 10.3109/08916931003674717, 43, 7, (478-492), (2010).
- I. Kötter and G. Horneff, IL-1-AntagonistenIL-1 antagonists, Zeitschrift für Rheumatologie, 10.1007/s00393-009-0530-7, 69, 7, (581-593), (2010).
- Michael P. Heffernan, Combining Traditional Systemic and Biologic Therapies for Psoriasis, Seminars in Cutaneous Medicine and Surgery, 10.1016/j.sder.2010.03.003, 29, 1, (67-69), (2010).
- Percy H Carter and Qihong Zhao, Clinically validated approaches to the treatment of autoimmune diseases, Expert Opinion on Investigational Drugs, 10.1517/13543780903418452, 19, 2, (195-213), (2010).
- Peter Härle, Rainer H. Straub and Martin Fleck, Perioperative management of immunosuppression in rheumatic diseases—what to do?, Rheumatology International, 10.1007/s00296-009-1323-7, 30, 8, (999-1004), (2009).
- D. Meyer-Olson, K. Hoeper and R.E. Schmidt, Infektionskomplikationen unter Biologika-Therapie bei Patienten mit rheumatoider ArthritisInfectious complications of biologic therapy in patients with rheumatoid arthritis, Zeitschrift für Rheumatologie, 10.1007/s00393-010-0677-2, 69, 10, (879-888), (2010).
- Yajing Hu, Deyong Liang, Xiangqi Li, Hong-Hsing Liu, Xun Zhang, Ming Zheng, David Dill, Xiaoyou Shi, Yanli Qiao, David Yeomans, Brendan Carvalho, Martin S. Angst, J. David Clark and Gary Peltz, The Role of Interleukin-1 in Wound Biology. Part II, Anesthesia & Analgesia, 10.1213/ANE.0b013e3181f691eb, 111, 6, (1534-1542), (2010).
- Anthony S. Russell, Wojtek P. Olszynski, K. S. Davison, Cheryl Koehn and Boulos Haraoui, Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy, Clinical Rheumatology, 10.1007/s10067-009-1338-1, 29, 3, (233-239), (2009).
- James Dale and Duncan Porter, Optimising the strategy of care in early rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2009.11.009, 24, 4, (443-455), (2010).
- Ewa M Paleolog, Angiogenesis in joint disease: the need for clinical data, International Journal of Clinical Rheumatology, 10.2217/ijr.10.41, 5, 4, (439-449), (2010).
- Terence Rooney, Carl K. Edwards, Martina Gogarty, Laura Greenan, Douglas J. Veale, Oliver FitzGerald, Jean-Michel Dayer and Barry Bresnihan, Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade, Rheumatology International, 10.1007/s00296-009-1191-1, 30, 12, (1571-1580), (2009).
- Christopher W. Espelin, Arthur Goldsipe, Peter K. Sorger, Douglas A. Lauffenburger, David de Graaf and Bart S. Hendriks, Elevated GM-CSF and IL-1β levels compromise the ability of p38 MAPK inhibitors to modulate TNFα levels in the human monocytic/macrophage U937 cell line, Molecular BioSystems, 10.1039/c002848g, 6, 10, (1956), (2010).
- Ranjeny Thomas, The Balancing Act of Autoimmunity: Central and Peripheral Tolerance Versus Infection Control, International Reviews of Immunology, 10.3109/08830180903434219, 29, 2, (211-233), (2010).
- P. Harle, R. H. Straub and M. Fleck, Elective surgery in rheumatic disease and immunosuppression: to pause or not, Rheumatology, 10.1093/rheumatology/keq049, 49, 10, (1799-1800), (2010).
- Charalampos Papagoras, Paraskevi V. Voulgari and Alexandros A. Drosos, Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis, Autoimmunity Reviews, 10.1016/j.autrev.2010.04.002, 9, 8, (574-582), (2010).
- S. Matsumoto, H. Noguchi, M. Takita, M. Shimoda, Y. Tamura, G. Olsen, B. Naziruddin, N. Onaca and M.F. Levy, ET-Kyoto Ductal Injection and Density-Adjusted Purification Combined With Potent Anti-Inflammatory Strategy Facilitated Single-Donor Islet Transplantation: Case Reports, Transplantation Proceedings, 10.1016/j.transproceed.2010.05.096, 42, 6, (2159-2161), (2010).
- Dan Lu, Sandhya Girish, Frank‐Peter Theil and Amita Joshi, Pharmacokinetic and Pharmacodynamic‐Based Drug Interactions for Therapeutic Proteins, Pharmaceutical Sciences Encyclopedia, (1-34), (2013).
- Joan Korth‐Bradley, Drug–Drug Interactions for Etanercept—A Fusion Protein, Pharmaceutical Sciences Encyclopedia, (1-8), (2013).
- Mark C. Fisher and Jeffrey D. Greenberg, Assessing infection risk with biologic agents in RA: methodological challenges, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.51, 5, 5, (288-291), (2009).
- Roy M. Fleischmann, Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab, Seminars in Arthritis and Rheumatism, 10.1016/j.semarthrit.2008.01.001, 38, 4, (265-280), (2009).
- Peter C. Taylor, IL-1 Inhibitors in the Treatment of Rheumatoid Arthritis, Rheumatoid Arthritis, 10.1016/B978-032305475-1.50047-1, (350-355), (2009).
- Alejandro Díaz-Borjón, Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis, Drugs & Aging, 10.2165/00002512-200926040-00001, 26, 4, (273-293), (2009).
- Karine Chauffier, Jonathan London, Constance Beaudouin and Bruno Fautrel, Indications de l’anakinra, La Presse Médicale, 10.1016/j.lpm.2009.01.012, 38, 5, (799-807), (2009).
- MARTY MERTENS and JASVINDER A. SINGH, Anakinra for Rheumatoid Arthritis: A Systematic Review, The Journal of Rheumatology, 10.3899/jrheum.090074, 36, 6, (1118-1125), (2009).
- Jason W. Bauer, Hatice Bilgic and Emily C. Baechler, Gene-expression profiling in rheumatic disease: tools and therapeutic potential, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.50, 5, 5, (257-265), (2009).
- Manfred Kunz and Saleh M. Ibrahim, Cytokines and Cytokine Profiles in Human Autoimmune Diseases and Animal Models of Autoimmunity, Mediators of Inflammation, 10.1155/2009/979258, 2009, (1-20), (2009).
- Laura J. Gibbons and Kimme L. Hyrich, Biologic Therapy for Rheumatoid Arthritis, BioDrugs, 10.2165/00063030-200923020-00004, 23, 2, (111-124), (2009).
- Hideki Kitaura, Yuji Fujimura, Masako Yoshimatsu, Toshiko Eguchi, Haruka Kohara, Insan Jang, Yukiko Morita and Noriaki Yoshida, An M-CSF Receptor c-Fms Antibody Inhibits Mechanical Stress–Induced Root Resorption during Orthodontic Tooth Movement in Mice, The Angle Orthodontist, 10.2319/080708-412.1, 79, 5, (835-841), (2009). 2009 2nd International Conference on Biomedical Engineering and Informatics Tianjin, China 2009 2nd International Conference on Biomedical Engineering and Informatics IEEE , (2009). 978-1-4244-4132-7 Qinglin Zha, Yiting He, Xiaorong Ding, Miao Jiang, Xuewen Liu, Cheng Lu, Ian Tsang and Aiping Lu The Predictive Role of Symptoms/signs on ACR20 Responses in Rheumatoid Arthritis Analyzed with Data Mining Approaches , (2009). 1 8 5302485 , 10.1109/BMEI.2009.5302485 http://ieeexplore.ieee.org/document/5302485/
- Hal M Hoffman, Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS), Expert Opinion on Biological Therapy, 10.1517/14712590902875518, 9, 4, (519-531), (2009).
- Rodney Tehrani, Rochella A Ostrowski, Richard Hariman and Walter M. Jay, Review of Biologic Therapies, Neuro-Ophthalmology, 10.3109/01658100903360064, 33, 6, (286-299), (2009).
- Siba P. Raychaudhuri, Caroline T. Nguyen, Smriti K. Raychaudhuri and M. Eric Gershwin, Incidence and nature of infectious disease in patients treated with anti-TNF agents, Autoimmunity Reviews, 10.1016/j.autrev.2009.08.006, 9, 2, (67-81), (2009).
- Peter C. Taylor and Marc Feldmann, Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, Nature Reviews Rheumatology, 10.1038/nrrheum.2009.181, 5, 10, (578-582), (2009).
- EUGENIE KOUMAKIS, JULIEN WIPFF, JEROME AVOUAC, ANDRE KAHAN and YANNICK ALLANORE, Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-α-Blocking Agents, The Journal of Rheumatology, 10.3899/jrheum.090160, 36, 9, (2125.2-2126), (2009).
- Yves Poulin and Marc Bourcier, Practical Aspects of Prescribing a Biologic, Journal of Cutaneous Medicine and Surgery, 13, 5_suppl, (S93), (2009).
- Y Shirota, GG Illei and NP Nikolov, Biologic treatments for systemic rheumatic diseases, Oral Diseases, 14, 3, (206-216), (2008).
- William P. Arend, Gaby Palmer and Cem Gabay, IL‐1, IL‐18, and IL‐33 families of cytokines, Immunological Reviews, 223, 1, (20-38), (2008).
- Maria A. Lopez‐Olivo, Michael A. Kallen, Zulma Ortiz, Becky Skidmore and Maria E. Suarez‐Almazor, Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review, Arthritis Care & Research, 59, 11, (1625-1638), (2008).
- Virginia Pascual, Florence Allantaz, Pinakeen Patel, A. Karolina Palucka, Damien Chaussabel and Jacques Banchereau, How the study of children with rheumatic diseases identified interferon‐α and interleukin‐1 as novel therapeutic targets, Immunological Reviews, 223, 1, (39-59), (2008).
- Marc Feldmann and Sir Ravinder N. Maini, Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics, Immunological Reviews, 223, 1, (7-19), (2008).
- Yiting He, Aiping Lu, Cheng Lu, Yinglin Zha, Xiaoping Yan, Yuejin Song, Shengping Zeng, Wei Liu, Wanhua Zhu, Li Su, Xinghua Feng, Xian Qian and Ian Tsang, Symptom Combinations Assessed in Traditional Chinese Medicine and Its Predictive Role in ACR20 Efficacy Response in Rheumatoid Arthritis, The American Journal of Chinese Medicine, 10.1142/S0192415X08006144, 36, 04, (675-683), (2008).
- Theodorus van den Broek, John RP Tesser and Salvatore Albani, The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care, Expert Opinion on Biological Therapy, 10.1517/147125126.96.36.1993, 8, 11, (1773-1785), (2008).
- Johan Askling and Will Dixon, The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis, Current Opinion in Internal Medicine, 10.1097/MCI.0b013e328303e7c3, 7, 3, (301-307), (2008).
- Kenneth G. Saag, Gim Gee Teng, Nivedita M. Patkar, Jeremy Anuntiyo, Catherine Finney, Jeffrey R. Curtis, Harold E. Paulus, Amy Mudano, Maria Pisu, Mary Elkins‐Melton, Ryan Outman, Jeroan J. Allison, Maria Suarez Almazor, S. Louis Bridges, W. Winn Chatham, Marc Hochberg, Catherine Maclean, Ted Mikuls, Larry W. Moreland, James O'dell, Anthony M. Turkiewicz and Daniel E. Furst, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis, Arthritis Care & Research, 59, 6, (762-784), (2008).
- Marcus D Köller, Targeted therapy in rheumatoid arthritis, Expert Opinion on Drug Discovery, 10.1517/174604188.8.131.529, 3, 3, (329-342), (2008).
- Edward M. Vital and Paul Emery, The development of targeted therapies in rheumatoid arthritis, Journal of Autoimmunity, 10.1016/j.jaut.2008.04.006, 31, 3, (219-227), (2008).
- William F. Fearon and Douglas T. Fearon, Inflammation and Cardiovascular Disease, Circulation, 10.1161/CIRCULATIONAHA.108.772491, 117, 20, (2577-2579), (2008).
- Yiting He, Aiping Lu, Yinglin Zha and Ian Tsang, Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients, Complementary Therapies in Medicine, 10.1016/j.ctim.2007.08.005, 16, 4, (206-211), (2008).
- Johan Askling and Will Dixon, The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis, Current Opinion in Rheumatology, 10.1097/BOR.0b013e3282f4b392, 20, 2, (138-144), (2008).
- George D Kalliolias and Stamatis-Nick C Liossis, The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis, Expert Opinion on Investigational Drugs, 10.1517/135437184.108.40.2069, 17, 3, (349-359), (2008).
- Rupa Pugashetti, Shilpa Gattu and John Koo, Adalimumab in the Treatment of Psoriasis, Moderate-to-Severe Psoriasis, Third Edition, 10.3109/9781420088687-14, (273-288), (2013).
- Yvonne Sherrer, Abatacept in biologic-naive patients and TNF inadequate responders: clinical data in focus, Current Medical Research and Opinion, 10.1185/03007990802223129, 24, 8, (2283-2294), (2008).
- William J. Koopman, Dawn of the era of biologics in the treatment of the rheumatic diseases, Arthritis & Rheumatism, 58, S2, (S75-S78), (2008).
- Joseph R Lutt and Atul Deodhar, Rheumatoid Arthritis, Drugs, 10.2165/00003495-200868050-00003, 68, 5, (591-606), (2008).
- Axel Finckh and Cem Gabay, At the horizon of innovative therapy in rheumatology: new biologic agents, Current Opinion in Rheumatology, 10.1097/BOR.0b013e3282fa13b4, 20, 3, (269-275), (2008).
- José de La Mata Llord, Rosa González Crespo and Jesús Maese Manzano, Tratamiento de la artritis reumatoide con anakinra: revisión sistemática, Reumatología Clínica, 10.1016/S1699-258X(07)73613-6, 3, 4, (153-158), (2007).
- Christoph Ackermann and Arthur Kavanaugh, Tumor necrosis factor as a therapeutic target of rheumatologic disease, Expert Opinion on Therapeutic Targets, 10.1517/14728220.127.116.119, 11, 11, (1369-1384), (2007).
- James B. Bussel, Lisa Giulino, Susan Lee, Vivek L. Patel, Christy Sandborg and E. Richard Stiehm, Update on Therapeutic Monoclonal Antibodies, Current Problems in Pediatric and Adolescent Health Care, 10.1016/j.cppeds.2007.02.001, 37, 4, (118-135), (2007).
- Olivier Meyer, Michel de Bandt, Jean-Marie Berthelot, Alain Cantagrel, Bernard Combe, Bruno Fautrel, René-Marc Flipo, Frédéric Lioté, Jean-Francis Maillefert, Alain Saraux, Daniel Wendling, Francis Guillemin and Xavier Le Loët, Arbre décisionnel permettant le choix en pratique clinique d'un traitement de fond de seconde intention au cours de la polyarthrite rhumatoïde récente, après échec d'un traitement de fond de première intention d'une durée de six mois, Revue du Rhumatisme, 10.1016/j.rhum.2006.11.001, 74, 1, (79-84), (2007).
- Jean-Marie Berthelot, Stéphane Varin, Grégoire Cormier, Laetitia Tortellier, Pascale Guillot, Joëlle Glemarec and Yves Maugars, Traitement par etanercept des polyarthrites rhumatoïdes et des spondylarthropathies à la posologie de 25 mg par semaine, Revue du Rhumatisme, 10.1016/j.rhum.2006.03.025, 74, 3, (237-241), (2007).
- Richard O. Williams, Ewa Paleolog and Marc Feldmann, Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases, Current Opinion in Pharmacology, 10.1016/j.coph.2007.06.001, 7, 4, (412-417), (2007).
- Lyn Guenther, Charles Lynde and Vincent Ho, Practical Considerations for the Initiation and Maintenance of Etanercept in the Treatment of Psoriasis, Journal of Cutaneous Medicine and Surgery, 10.2310/7750.2006.00072, 11, 2_suppl, (S37-S47), (2016).
- José de La Mata Llord, Rosa González Crespo and Jesús Maese Manzano, Treatment of Rheumatoid Arthritis With Anakinra: A Systematic Review, Reumatología Clínica (English Edition), 10.1016/S2173-5743(07)70237-X, 3, 4, (153-158), (2007).
- Olivier Meyer, Michel de Bandt, Jean-Marie Berthelot, Alain Cantagrel, Bernard Combe, Bruno Fautrel, René-Marc Flipo, Frédéric Lioté, Jean-Francis Maillefert, Alain Saraux, Daniel Wendling, Francis Guillemin and Xavier Le Loët, Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6months' first-line DMARD therapy, Joint Bone Spine, 10.1016/j.jbspin.2006.05.008, 74, 1, (73-78), (2007).
- Kim A. Papp, Edward C. Keystone and Neil H. Shear, Mechanism of Action, Pharmacokinetics, and Drug Interactions of Etanercept in Dermatology, Journal of Cutaneous Medicine and Surgery, 10.2310/7750.2006.00069, 11, 2_suppl, (S3-S13), (2016).
- Jeffrey P. Callen, Complications and Adverse Reactions in the Use of Newer Biologic Agents, Seminars in Cutaneous Medicine and Surgery, 10.1016/j.sder.2006.12.002, 26, 1, (6-14), (2007).
- Jean-Marie Berthelot, Stéphane Varin, Grégoire Cormier, Laetitia Tortellier, Pascale Guillot, Joëlle Glemarec and Yves Maugars, 25mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy, Joint Bone Spine, 10.1016/j.jbspin.2006.03.010, 74, 2, (144-147), (2007).
- Dan C Nordström, Anakinra in the treatment of rheumatoid arthritis and other IL-1-driven conditions, Future Rheumatology, 10.2217/17460818.104.22.1683, 2, 4, (353-360), (2007).
- T Cobo-Ibáñez and E Martín-Mola, Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis, Expert Opinion on Pharmacotherapy, 10.1517/14656522.214.171.1243, 8, 9, (1373-1397), (2007).
- Steven C Ghivizzani, Elvire Gouze, Rachael S Watson, Jeetpaul Saran, Jesse D Kay, Marsha L Bush, Padraic P Levings and Jean-Noel Gouze, Interleukin-1 in Rheumatoid Arthritis: Its Inhibition by IL-1Ra and Anakinra, Journal of Pharmacy Technology, 10.1177/875512250702300205, 23, 2, (86-94), (2016).
- Allen P Anandarajah and Christopher T Ritchlin, Infliximab in psoriatic arthritis, Future Rheumatology, 10.2217/174608126.96.36.199, 2, 1, (13-22), (2007).
- Thierry Lequerré, Olivier Vittecoq and Xavier Le Loët, Quelle est la place actuelle de l'IL-1Ra dans les maladies rhumatismales?, Revue du Rhumatisme, 10.1016/j.rhum.2006.10.670, 74, 5, (435-439), (2007).
- Peter C Taylor, The future of TNF-α antagonism, Future Rheumatology, 10.2217/174608188.8.131.52, 2, 3, (233-236), (2007).
- Jean Lee and Hongjin Ma, Specificity and selectivity evaluations of ligand binding assay of protein therapeutics against concomitant drugs and related endogenous proteins, The AAPS Journal, 10.1208/aapsj0902018, 9, 2, (E164-E170), (2007).
- Vibeke Strand, Robert Kimberly and John D. Isaacs, Biologic therapies in rheumatology: lessons learned, future directions, Nature Reviews Drug Discovery, 10.1038/nrd2196, 6, 1, (75-92), (2007).
- Thierry Lequerré, Olivier Vittecoq and Xavier le Loët, What is the role for interleukin-1 receptor antagonist in rheumatic disease?, Joint Bone Spine, 10.1016/j.jbspin.2006.10.006, 74, 3, (223-226), (2007).
- Jung-Soo Song, Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis, The Journal of the Korean Rheumatism Association, 10.4078/jkra.2007.14.1.1, 14, 1, (1), (2007).
- E. Montané, M. Sallés, A. Barriocanal, E. Riera, J. Costa and X. Tena, Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges, Clinical Rheumatology, 10.1007/s10067-006-0415-y, 26, 9, (1527-1529), (2006).
- Ulrich Klotz, Alexander Teml and Matthias Schwab, Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, 10.2165/00003088-200746080-00002, 46, 8, (645-660), (2007).
- Esther van de Vosse and Michiel A van Agtmael, Targets of anticytokine therapy and the risk of infections in humans and mice, Current Opinion in Rheumatology, 10.1097/BOR.0b013e3282f05c6d, 19, 6, (626-635), (2007).
- Lisa Lundquist, Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis, Advances in Therapy, 10.1007/BF02849902, 24, 2, (333-345), (2007).
- M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J. C. Becker and E. Keystone, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study, Arthritis & Rheumatism, 54, 9, (2807-2816), (2006).
- A.I. Snchez Atrio, A. Prez Gmez, E. Cuende Quintana and A. Turrin Nieves, Aspectos actuales y perspectivas de futuro del tratamiento de la artritis reumatoide, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 10.1016/S0211-3449(06)74450-2, 9, 69, (4436-4442), (2006).
- Gary Kunkel and Grant W Cannon, Leflunomide in the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 10.1586/1744666X.2.1.17, 2, 1, (17-31), (2014).
- Sarah TA Roord, Berent J Prakken and Salvatore Albani, Present and future of combination therapy of autoimmune diseases, Future Rheumatology, 10.2217/174608184.108.40.2069, 1, 6, (649-655), (2006).
- Allan Gibofsky, Combination Therapy for Rheumatoid Arthritis in the Era of Biologicals, HSS Journal, 10.1007/s11420-005-0133-z, 2, 1, (30-41), (2006).
- Bruno Fautrel, Arnaud Constantin, Jacques Morel, Olivier Vittecoq, Alain Cantagrel, Bernard Combe, Maxime Dougados, Xavier Le Loët, Xavier Mariette, Thao Pham, Xavier Puéchal, Jean Sibilia, Martin Soubrier and Philippe Ravaud, Recommandations de la Société française de rhumatologie pour l'utilisation des agents anti-TNFα chez les personnes souffrant de polyarthrite rhumatoïde, Revue du Rhumatisme, 10.1016/j.rhum.2006.04.005, 73, 7, (726-735), (2006).
- SUSAN J. LEE and ARTHUR KAVANAUGH, Biologic Agents in Rheumatology: Safety Considerations, Rheumatic Disease Clinics of North America, 10.1016/S0889-857X(07)70003-0, 32, (3-10), (2006).
- Eric M Ruderman and Richard M Pope, Drug Insight: abatacept for the treatment of rheumatoid arthritis, Nature Clinical Practice Rheumatology, 10.1038/ncprheum0345, 2, 12, (654-660), (2006).
- Kenneth B. Gordon and Eric M. Ruderman, The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach, Journal of the American Academy of Dermatology, 10.1016/j.jaad.2005.10.052, 54, 3, (S85-S91), (2006).
- SARAH MACKIE, MARK QUINN and PAUL EMERY, Rheumatoid Arthritis, The Autoimmune Diseases, 10.1016/B978-012595961-2/50035-4, (417-436), (2006).
- Christine Savage and E. William St. Clair, New Therapeutics in Rheumatoid Arthritis, Rheumatic Disease Clinics of North America, 10.1016/j.rdc.2005.10.004, 32, 1, (57-74), (2006).
- Roy Fleischmann, Safety and efficacy of etanercept in the elderly, Aging Health, 10.2217/1745509X.2.2.189, 2, 2, (189-197), (2006).
- Bruno Fautrel, Arnaud Constantin, Jacques Morel, Olivier Vittecoq, Alain Cantagrel, Bernard Combe, Maxime Dougados, Xavier Le Loët, Xavier Mariette, Thao Pham, Xavier Puéchal, Jean Sibilia, Martin Soubrier and Philippe Ravaud, Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis, Joint Bone Spine, 10.1016/j.jbspin.2006.04.001, 73, 4, (433-441), (2006).
- Roy Fleischmann, Anakinra in the treatment of rheumatic disease, Expert Review of Clinical Immunology, 10.1586/1744666X.2.3.331, 2, 3, (331-340), (2014).
- Danielle Burger, Jean-Michel Dayer, Gaby Palmer and Cem Gabay, Is IL-1 a good therapeutic target in the treatment of arthritis?, Best Practice & Research Clinical Rheumatology, 10.1016/j.berh.2006.06.004, 20, 5, (879-896), (2006).
- Bart JF van den Bemt, Frank HJ van den Hoogen, Ferdinand C Breedveld,, Hille van der Tempel and Rob Janknegt, InforMatrix ® : treatment of rheumatoid arthritis using biologicals , Expert Opinion on Pharmacotherapy, 10.1517/146565220.127.116.119, 7, 13, (1769-1789), (2006).
- Claire Jacques, Marjolaine Gosset, Francis Berenbaum and Cem Gabay, The Role of IL‐1 and IL‐1Ra in Joint Inflammation and Cartilage Degradation, Interleukins, 10.1016/S0083-6729(06)74016-X, (371-403), (2006).
- Burkhard Möller and Peter M. Villiger, Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases, Springer Seminars in Immunopathology, 10.1007/s00281-006-0012-9, 27, 4, (391-408), (2006).
- Angelo Gaffo, Kenneth G. Saag and Jeffrey R. Curtis, Treatment of rheumatoid arthritis, American Journal of Health-System Pharmacy, 10.2146/ajhp050514, 63, 24, (2451-2465), (2006).
- Frank Pucino, Phyllis Tish Harbus and Raphaela Goldbach-Mansky, Use of biologics in rheumatoid arthritis: Where are we going?, American Journal of Health-System Pharmacy, 10.2146/ajhp060365, 63, 18_Supplement_4, (S19-S41), (2006).
- Bo Baslund, Niels Tvede, Bente Danneskiold‐Samsoe, Per Laon, Gabriel Panayi, Joergen Petersen, Lars J. Petersen, Frank J. M. Beurskens, Janine Schuurman, Jan G. J. van de Winkel, Paul W. H. I. Parren, J. Alastair Gracie, Sarah Jongbloed, Foo Y. Liew and Iain B. McInnes, Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study, Arthritis & Rheumatism, 52, 9, (2686-2692), (2005).
- David J. Rychly and Joseph T. DiPiro, Infections Associated with Tumor Necrosis Factor‐α Antagonists, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 25, 9, (1181-1192), (2012).
- Honghui Zhou, Clinical Pharmacokinetics of Etanercept: A Fully Humanized Soluble Recombinant Tumor Necrosis Factor Receptor Fusion Protein, The Journal of Clinical Pharmacology, 45, 5, (490-497), (2013).
- Lucia Shuk Yi CHAU, Chi Chiu MOK and Ernest CHOY, Non‐tumor necrosis factor biological therapies for rheumatoid arthritis, APLAR Journal of Rheumatology, 8, 2, (77-83), (2005).
- Virginia Pascual, Florence Allantaz, Edsel Arce, Marilynn Punaro and Jacques Banchereau, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, The Journal of Experimental Medicine, 10.1084/jem.20050473, 201, 9, (1479-1486), (2005).
- Gregory C. Gardner, Inflammatory arthritis in the era of the biologics, Clinical and Applied Immunology Reviews, 10.1016/j.cair.2004.11.001, 5, 1, (19-44), (2005).
- Mathias Grunke and Joachim Robert Kalden, Etanercept: an introduction, Expert Review of Clinical Immunology, 10.1586/1744666X.1.3.313, 1, 3, (313-323), (2014).
- Virginia Pascual, Karolina Palucka and Jacques Banchereau, Role of innate immunity cytokines in systemic lupus and systemic onset arthritis, International Congress Series, 10.1016/j.ics.2005.08.018, 1285, (50-54), (2005).
- Susan J. Lee and Arthur Kavanaugh, Adverse reactions to biologic agents: Focus on autoimmune disease therapies, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2005.03.028, 116, 4, (900-905), (2005).
- C.M. Gonzlez Fernndez, J. Vzquez Prez-Coleman, M. Montoro lvarez and L. Carreo Prez, Tratamiento biol?gico de las enfermedades reum?ticas, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 10.1016/S0211-3449(05)73559-1, 9, 28, (1830-1839), (2005).
- Robert J. Smith, Therapies for rheumatoid arthritis: hope springs eternal, Drug Discovery Today, 10.1016/S1359-6446(05)03636-6, 10, 23-24, (1598-1606), (2005).
- H. U. Scherer and G. R. Burmester, RheumatologieRheumatology, Der Internist, 10.1007/s00108-005-1444-3, 46, 8, (882-891), (2005).
- Marc Feldmann and Lawrence Steinman, Design of effective immunotherapy for human autoimmunity, Nature, 10.1038/nature03727, 435, 7042, (612-619), (2005).
- Ignazio Olivieri, Carlo Palazzi, Giovanni Peruz and Angela Padula, Management Issues with Elderly-Onset Rheumatoid Arthritis, Drugs & Aging, 10.2165/00002512-200522100-00002, 22, 10, (809-822), (2005).
- Pierre Miossec, Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments, Molecular Autoimmunity, 10.1007/0-387-24534-0_23, (329-345), (2005).
- Louise Pollard and Ernest Choy, Rheumatoid arthritis: non-tumor necrosis factor targets, Current Opinion in Rheumatology, 10.1097/01.bor.0000159927.19891.eb, 17, 3, (242-246), (2005).
- P. J. M. M. Toll, Behandeling van reuma met de combinatie van etanercept en anakinra, Medisch-Farmaceutische Mededelingen, 10.1007/BF03058427, 42, 7, (196-196), (2004).
- U. M�ller-Ladner, ?Biologics? bei der rheumatoiden ArthritisCost effectiveness of biologics in the treatment of rheumatoid arthritis, Der Internist, 10.1007/s00108-004-1297-1, 45, 12, (1402-1406), (2004).
- Xavier Mariette, Biothérapies émergentes dans la polyarthrite rhumatoïde, Revue du Rhumatisme, 10.1016/j.rhum.2004.07.012, 71, 10-11, (848-853), (2004).
- Yuti Chernajovsky, David J. Gould and Osvaldo L. Podhajcer, Gene therapy for autoimmune diseases: quo vadis?, Nature Reviews Immunology, 10.1038/nri1459, 4, 10, (800-811), (2004).
- Roy Fleischmann, Richard Stern and Imran Iqbal, Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis, Expert Opinion on Biological Therapy, 10.1517/14712518.104.22.1683, 4, 8, (1333-1344), (2005).
- Luciano Adorini, A comparison of cytokine-based approaches to treat autoimmune disorders, Drug Discovery Today: Therapeutic Strategies, 10.1016/j.ddstr.2004.09.010, 1, 3, (275-280), (2004).
- Roy M Fleischmann, Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective, Therapy, 10.2217/14750708.1.2.255, 1, 2, (255-266), (2004).
- Amanda Burls and Paresh Jobanputra, The trials of anakinra, The Lancet, 10.1016/S0140-6736(04)16999-7, 364, 9437, (827-828), (2004).
- Michael H Schiff, Durability and Rapidity of Response to Anakinra in Patients with Rheumatoid Arthritis, Drugs, 10.2165/00003495-200464220-00001, 64, 22, (2493-2501), (2004).
- Peter C. Taylor and Marc Feldmann, Rheumatoid arthritis: pathogenic mechanisms and therapeutic targets, Drug Discovery Today: Disease Mechanisms, 10.1016/j.ddmec.2004.10.006, 1, 3, (289-295), (2004).
- Xavier Mariette, Emerging biological therapies in rheumatoid arthritis, Joint Bone Spine, 10.1016/j.jbspin.2004.07.008, 71, 6, (470-474), (2004).
- Peter C Taylor, Richard O Williams and Marc Feldmann, Tumour necrosis factor α as a therapeutic target for immune-mediated inflammatory diseases, Current Opinion in Biotechnology, 10.1016/j.copbio.2004.09.005, 15, 6, (557-563), (2004).
- Michael Croft and Richard M. Siegel, Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases, Nature Reviews Rheumatology, 10.1038/nrrheum.2017.22, 13, 4, (217-233), (2017)., (2017).
- Xavier Chevalier, Florent Eymard and Pascal Richette, Biologic agents in osteoarthritis: hopes and disappointments, Nature Reviews Rheumatology, 10.1038/nrrheum.2013.44, 9, 7, (400-410), (2013)., (2013).
- Judy H Cho and Marc Feldman, Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies, Nature Medicine, 10.1038/nm.3897, 21, 7, (730-738), (2015)., (2015).
- Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Lara J Maxwell, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Maria E Suarez-Almazor, Peter Tugwell and George A Wells, Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012591, (2017).
- Josef S. Smolen, Daniel Aletaha and Kurt Redlich, The pathogenesis of rheumatoid arthritis: new insights from old clinical data?, Nature Reviews Rheumatology, 10.1038/nrrheum.2012.23, 8, 4, (235-243), (2012)., (2012).
- N. Blank, R. Max, M. Schiller, S. Briem and H.-M. Lorenz, Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis, Rheumatology, 10.1093/rheumatology/ken491, 48, 4, (440-441), (2009).
- Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell and George A Wells, Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA), Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012437, (2016).
- Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell and George A Wells, Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012183, (2016).
- George D. Kalliolias and Lionel B. Ivashkiv, TNF biology, pathogenic mechanisms and emerging therapeutic strategies, Nature Reviews Rheumatology, 10.1038/nrrheum.2015.169, 12, 1, (49-62), (2015)., (2015).
- Marty Mertens and Jasvinder A Singh, Anakinra for rheumatoid arthritis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005121.pub3, (2009).
- Ernest H. Choy, Arthur F. Kavanaugh and Simon A. Jones, The problem of choice: current biologic agents and future prospects in RA, Nature Reviews Rheumatology, 10.1038/nrrheum.2013.8, 9, 3, (154-163), (2013)., (2013).
- Y. Yazici, N. M. Adler and H. Yazici, Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations, Rheumatology, 10.1093/rheumatology/ken190, 47, 7, (1054-1057), (2008).
- Jasvinder A Singh, Alomgir Hossain, Amy S Mudano, Elizabeth Tanjong Ghogomu, Maria E Suarez-Almazor, Rachelle Buchbinder, Lara J Maxwell, Peter Tugwell and George A Wells, Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD012657, (2017).
- Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell and Rachelle Buchbinder, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008794.pub2, (2011).
- Yuan Weifeng, Li Li, Hu Yujie, Li Weifeng, Guo Zhenhui and Huang Wenjie, Inhibition of Acute Lung Injury by TNFR-Fc through Regulation of an Inflammation-Oxidative Stress Pathway, PLOS ONE, 10.1371/journal.pone.0151672, 11, 3, (e0151672), (2016).
- Yinon Ben-Neriah and Michael Karin, Inflammation meets cancer, with NF-κB as the matchmaker, Nature Immunology, 10.1038/ni.2060, 12, 8, (715-723), (2011)., (2011).
- Mathieu Ferrari, Shimobi C. Onuoha and Costantino Pitzalis, Trojan horses and guided missiles: targeted therapies in the war on arthritis, Nature Reviews Rheumatology, 10.1038/nrrheum.2015.17, 11, 6, (328-337), (2015)., (2015).
- Philipp Rein and Ruediger B. Mueller, Treatment with Biologicals in Rheumatoid Arthritis: An Overview, Rheumatology and Therapy, 10.1007/s40744-017-0073-3, (2017).
- Anne Lethaby, Maria Angeles Lopez-Olivo, Lara J Maxwell, Amanda Burls, Peter Tugwell and George A Wells, Etanercept for the treatment of rheumatoid arthritis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004525.pub2, (2013).
- Jason M. Rosenzweig, Jun Lei and Irina Burd, Interleukin-1 Receptor Blockade in Perinatal Brain Injury, Frontiers in Pediatrics, 10.3389/fped.2014.00108, 2, (2014).
- Minyoung Her and Arthur Kavanaugh, Advances in use of immunomodulatory agents—a rheumatology perspective, Nature Reviews Gastroenterology & Hepatology, 10.1038/nrgastro.2015.65, 12, 6, (363-368), (2015)., (2015).
- Mark C Genovese, Michael E Weinblatt, Philip J Mease, Jacob A Aelion, Paul M Peloso, Kun Chen, Yihan Li, John Liu, Ahmed A Othman, Amit Khatri, Heikki T Mansikka and Piotr Leszczyński, Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis, Rheumatology, 10.1093/rheumatology/key173, (2018).
- Sudarshan Paramsothy, Adam K. Rosenstein, Saurabh Mehandru and Jean-Frederic Colombel, The current state of the art for biological therapies and new small molecules in inflammatory bowel disease, Mucosal Immunology, 10.1038/s41385-018-0050-3, (2018).
- Mojtaba Abbasi, Mohammad Javad Mousavi, Sirous Jamalzehi, Reza Alimohammadi, Maryam Hasanzadeh Bezvan, Hamed Mohammadi and Saeed Aslani, Strategies toward rheumatoid arthritis therapy; the old and the new, Journal of Cellular Physiology, , (2018).